CytoHub

CytoHub’s native AI, trained on proprietary human heart data no one else can replicate, already powers a revenue engine growing more than tenfold in five years, with customers like Eli Lilly acquired and a paid pilot locked in with Johnson & Johnson. That same AI drives HeartReady, a heart failure therapy valued at $227M, in a category where recent deals have hit billions. We’re closing $2M now to materialize an already-signed $40M strategic term sheet, giving you proven revenue today and a fully funded shot at curing heart disease tomorrow.